Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401068 | 1.00 | PDE9A (1.00) | PDE9APDE1C | |
| SCHEMBL12401052 | 1.00 | PDE9A (1.00) | PDE9APDE1C | |
| SCHEMBL12401308 | 0.99 | PDE9A (0.98) | PDE9APDE1C | |
| SCHEMBL12401081 | 0.97 | PDE9A (0.95) | PDE9APDE1C | |
| SCHEMBL12401038 | 0.97 | PDE9A (0.95) | PDE9APDE1C | |
| SCHEMBL7888087 | 0.92 | PDE9A (0.85) | PDE9APDE1C | |
| SCHEMBL7880516 | 0.92 | PDE9A (0.85) | PDE9APDE1C | |
| SCHEMBL7877644 | 0.92 | PDE9A (0.84) | PDE9APDE1C | |
| SCHEMBL2531298 | 0.91 | PDE9A (0.83) | PDE9APDE1C | |
| SCHEMBL6340000 | 0.91 | PDE9A (0.83) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067945-B2 | Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes | Boehringer Ingehleim International GmbH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9067945-B2 | Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes | Boehringer Ingehleim International GmbH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9067945-B2 | Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes | Boehringer Ingehleim International GmbH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-8741907-B2 | Alkyl-substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8741907-B2 | Alkyl-substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8741907-B2 | Alkyl-substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8623879-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20130245045-A1 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245045-A1 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245045-A1 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20100210839-A1 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-7737156-B2 | 6-(Cyclohexylmethyl)-1-(1-ethylpropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, administered to humans or animals, to improve perception, concentration, cognition, learning and/or memory, as a consequence of dementia, stroke, brain trauma, Alzheimer's disease, Parkinson's disease or depression | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737156-B2 | 6-(Cyclohexylmethyl)-1-(1-ethylpropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, administered to humans or animals, to improve perception, concentration, cognition, learning and/or memory, as a consequence of dementia, stroke, brain trauma, Alzheimer's disease, Parkinson's disease or depression | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737156-B2 | 6-(Cyclohexylmethyl)-1-(1-ethylpropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, administered to humans or animals, to improve perception, concentration, cognition, learning and/or memory, as a consequence of dementia, stroke, brain trauma, Alzheimer's disease, Parkinson's disease or depression | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20060111372-A1 | Alkyl-substituted pyrazolopyrimidines | BAYER HEALTHCARE AG (DE) | 2006-05-25 | — | — | US | disclosed |
| US-20060100222-A1 | Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| EP-1534713-B1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1534713-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | Bayer HealthCare AG (DE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004026286-A2 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | BAYER HEALTHCARE AG (DE) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026876-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210839-A1 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE1C 19/4885 |
| US-20130245045-A1 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE1C 19/4885 |
| US-20060111372-A1 | Alkyl-substituted pyrazolopyrimidines | P2RX4, P2RX5, P2RY4 | PDE9A 450/4885PDE1C 753/4885 |
| US-20060100222-A1 | Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE1C 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.